GMP ICHQ7 compliance is a critical benchmark for the pharmaceutical and biotechnology industries, ensuring that products are produced consistently and abide by the highest quality standards. Oligo Factory has implemented a comprehensive quality management system to align its operations with GMP guidelines. This includes enhanced documentation and traceability practices, rigorous training programs for employees, regular audits, and continuous improvement initiatives. By integrating these measures into its manufacturing process, Oligo Factory can now serve its customer base more fully and enhance the level of quality and consistency across its oligonucleotide products.

“We are thrilled to announce our GMP ICHQ7 compliance. I’m extremely proud of our team who worked tirelessly throughout 2023 to achieve this milestone,” said Chris Boggess, CEO of Oligo Factory. “This accomplishment reflects our unwavering commitment to producing oligonucleotides of the highest quality to meet the growing demand from our valued customers in the pharmaceutical and biotech industries.”

Oligo Factory’s GMP-compliant products support a range of applications, including drug discovery, therapeutic development, diagnostic testing, and more. In early 2023, Oligo Factory opened a state-of-the-art oligonucleotide synthesis facility in Holliston, MA, to meet growing demand for its services. The new facility, with over 13,000 sq ft of laboratory and office space, increases oligo synthesis capacity by 12x and purification and lyophilization by 10x.

The post Oligo Factory Announces GMP Compliance appeared first on MassBio.

BOSTON, Massachusetts, January 3, 2024 — Today marks a significant milestone for Prendio and BioProcure, industry leaders in cloud-based eProcurement software and procure-to-pay support services for the life sciences sector, as they proudly announce the appointment of Eric Meizlish as their new Chief Executive Officer. This corresponds with Vincent Bologna’s transition from his operational role as CEO to a Board position, following a strategic growth investment from Primus Capital.

Eric Meizlish, a seasoned entrepreneur, operator, and technology investor, expresses his enthusiasm for the new role: “I’m thrilled to step into the role of CEO at Prendio and BioProcure. Since 2007, Prendio and BioProcure have been committed to the mission of simplifying and optimizing procurement for life science organizations, enabling them to focus on their core research and development. I am honored to lead the future expansion and to deliver financial and operational innovation and efficiency for high-growth life science companies of all stages.”

Eric has a strong track record leading technology businesses in healthcare. He was a co-founder of Lumere, a software and clinical analytics innovator for supply chain teams within hospitals and health systems, where he served as its President and Chief Strategy Officer until its acquisition by GHX in early 2020. At GHX, he served as the Senior Vice President of Strategy and Corporate Development and was a member of the global leadership team. He also has experience investing in high growth businesses, including several years managing portfolios of publicly traded equities at Citadel. He holds a degree in Economics and Mathematics from Yale University.

Vincent Bologna, Co-founder and outgoing CEO of Prendio and BioProcure stated, “As I transition from my role as CEO, I am proud of the incredible accomplishments we’ve achieved at Prendio and BioProcure. It’s been an honor to work alongside talented teams and visionary leaders. I have full confidence in Eric Meizlish to lead the companies into a new era of success. My sincere thanks to everyone who has been part of this journey. I look forward to contributing to the continued growth and prosperity of Prendio and BioProcure at the board level.”

Eric begins his new role as CEO representing Prendio and BioProcure at JPM Week ‘24 in San Francisco.

About Prendio
Prendio is an industry leading, cloud-based eProcurement solution created specifically for the life science vertical. Built by a team of industry professionals with over fifty combined years of experience in biotech procurement, lab management, and finance, the Prendio software was designed to relieve the pain points felt by research teams struggling with cumbersome and inefficient procure-to-pay systems. Prendio is an affordable, intuitive, and scalable solution designed to accelerate the progress of life science teams everywhere. For more information, visit https://prendio.com.

About BioProcure
Since 2007, BioProcure has been instrumental to the success of hundreds of emerging and established life science companies worldwide. By providing procurement services, accounts payable support, and other administrative assistance to research organizations, the BioProcure team has succeeded in securing billions of dollars in cost savings for the biotech research organizations they serve, and relieving

lab teams of countless hours of administrative work, allowing them to invest more of their time and funding into their science and drive discovery faster. For more information, visit https://bioprocure.com.

Media Contact:

Jeannette Franklin

Sr. Marketing Manager

media@prendio.com

(888) 710-9996

The post BioProcure and Prendio Appoint Eric Meizlish as New CEO appeared first on MassBio.

Download
this article to learn how to improve accuracy, boost throughput, and
reduce errors in your identification process.

The post Advanced Sample Identification and Labware Preparation appeared first on MassBio.

Boston Globe Big Night Live Award Ceremony, November 29, 2023. Left to Right: Sean Loughran, BioProcure Purchasing Manager, Jeannette Franklin, BioProcure/Prendio Sr. Marketing Manager, Christina Hem, Prendio Jr. Business Analyst, Tyler Mizenko, BioProcure/Prendio VP of Relationships and Business Development, Laura Stack, BioProcure/Prendio Co-Founder and COO, Vincent Bologna, BioProcure/Prendio Co-Founder and CEO, Marie Lodi, BioProcure/Prendio VP of HR, Brianna O’Brien, BioProcure Procurement Supervisor, Claire Buckley, BioProcure Customer Support Manager, and Daniel Simons, BioProcure/Prendio Financial Analyst

From a small home office in the founders’ unfinished attic to #1 Best Place to Work— BioProcure/Prendio has certainly evolved, but some things remain the same.

2023 has been a pivotal year for BioProcure and Prendio. This past October the companies announced a strategic investment from Primus Capital to accelerate growth and innovation across all services and offerings. Now, just over a month later, we are sharing more exciting news: BioProcure/Prendio has been named the #1 Best Place to Work in Massachusetts by the Boston Globe. 

“When we heard that we’d been selected by the Globe as one of the Top Places to Work in Massachusetts, we were thrilled,” said Laura Stack, co-founder and COO of BioProcure and Prendio. “Winning #1 Best Place to Work in the mid-sized company category was a huge surprise!” 

“I’m still surprised that we are considered a mid-sized company,” added Vincent Bologna, co-founder and CEO of BioProcure and Prendio. “In my mind, we’re just a small family business.” 

It’s safe to say that many of BioProcure and Prendio’s team members would agree with Bologna on that point—and perhaps the tight-knit, family feel is one of the reasons for this win. Bologna and Stack—a husband and wife team who met on the job at Wang Laboratories and worked together professionally in various capacities in the following years—originally hired other immediate family members to help them as their business grew: daughters, sons-in-law, brothers, nieces and nephews.

“I remember how excited we were to hire our first non-family co-worker,” said Kara Rea, BioProcure and Prendio’s Marketing Manager and Bologna and Stack’s oldest daughter. “We had just moved into our first real office. It had three tiny little rooms, and we were like, wow! We’re an actual company now, this is all so official! Laura and I sat down to interview Johnna Worob, and the three of us were trying our best to come across as very professional. At one point Laura said, ‘I’m sorry, but I have to be honest with you… You need to know that you’ll be the only one in here who isn’t related to everyone else.’ And Johnna was just like, ‘Oh, great. You guys are nuts, aren’t you?’ By the end of the interview we were all in tears laughing. Johnna’s been with us for almost eleven years now.”

Work meeting at the expanded Woburn office, 2017. Left to Right: Laura Stack, BioProcure/Prendio Co-Founder and COO, Lindsay Gross, BioProcure Procurement Supervisor, AZ Office, Jim Bukartek, Prendio Sr. Director of Product Success, and Vincent Bologna, BioProcure/Prendio Co-Founder and CEO

Hiring continued as demand for the life science procurement and accounts payable support services offered by BioProcure increased. In 2014 Sean Loughran, BioProcure’s Purchasing Manager, joined the team as a Procurement Specialist. Shortly afterward Tyler Mizenko, BioProcure/Prendio’s VP of Relationships and Business Development was hired as a Customer Support Intern. Laurie Martin was the company’s first Accounts Payable Specialist hire in 2015. After multiple promotions, she is now the Senior Manager of HRIS Benefits and Compliance for BioProcure/Prendio.  

When the need for a specialized life science procurement tool became apparent in 2015, BioProcure had roughly 20 employees, all of whom were tapped to lend their experience in procurement and accounts payable for biotech companies in the effort to build a software to fit the specific needs of an expanding client base. Some of those employees ended up officially transitioning to the Prendio team—like sisters Christina and Amanda Hem, who started as Accounts Payable and Procurement Specialists, and have since been promoted to Prendio’s Junior Business Analyst and eCommerce Specialist, and Jim Bukartek, who was hired as a BioProcure Procurement Specialist in 2015 but quickly rose to Prendio leadership. This past month, Jim was promoted again to Senior Director of Product Success.

BioProcure and Prendio have a total of 186 employees as of this article’s release, working hybrid or in-person from the office headquarters in Woburn, MA, the Western office in Chandler, Arizona, and virtually from all over the United States. In 2024 another move is planned, to an even larger headquarters based in Burlington, MA. 

It’s a big step up from the first company headquarters in the unfinished attic space of the couple’s home in Lexington, MA, where Bologna, Stack, and Rea worked long hours together while Laura’s brother Tim Stack placed orders remotely from upstate New York. “I’m pretty sure my desk was actually an old door balanced across two filing cabinets,” Rea remembers with a laugh. “A lot has changed in the last sixteen years!”

Kara Rea, BioProcure/Prendio Marketing Manager, pictured with office cat Suzi in 2009 in the original BioProcure headquarters in the attic of Bologna and Stack’s home

And while that statement is certainly true, some things—like the “BioProcure Way” philosophy, now solidified into seven core company values—have stayed very much the same. “We want to help facilitate success,” Bologna clarifies. “It’s the whole reason behind everything we do. We want to help labs and scientists succeed in their research. We want to help venture firms plant and grow new startups, to do whatever we can to conserve their resources so they can make important discoveries that will help people. But it doesn’t end with the clients. Our mission extends to each other–we want to see each other succeed. That’s why we love promoting from within, and why we’ve done that from the beginning. We want to support families with a great work/life balance. We want to be the kind of place where people feel included, and secure, and happy, where they know that if they work hard, their efforts won’t be wasted. That’s always been the goal.”

Vincent Bologna, BioProcure/Prendio Co-Founder and CEO, pictured with Suzi the office cat in the original BioProcure attic headquarters, 2009

According to the results of the employee survey conducted by the Boston Globe in April of 2023, BioProcure and Prendio are hitting that goal. The results showed that team members most often described the company as ‘inclusive’, ‘connected’, ‘supportive’, ‘positive’, ‘friendly’, and ‘motivating’. Others mentioned that BioProcure and Prendio are ‘customer-focused’, ‘compassionate’, and ‘value teamwork’.  

There is another word that BioProcure/Prendio team members used repeatedly to describe their company in the survey results. You can probably guess by this point what the word is.

Family.

BioProcure and Prendio were presented with the Boston Globe award for #1 Best Place To Work in Massachusetts on Wednesday, November 29, 2023. Click here to read the featured article on the Globe website. 

The post BioProcure/Prendio Named #1 Best Place To Work In Massachusetts By The Boston Globe appeared first on MassBio.

Harvard Medical School Center for BioethicsHarvard Medical School Center for Bioethics5d • 

The post Harvard Medical School: Master of Science in Bioethics: Accepting Application: bioethics.hms.harvard.edu appeared first on MassBio.

What these stories have in common is a mindset that continues to drive our organization: Your future is limitless. When we work together to create positive change, overcome challenges, and explore what’s possible, there really isn’t any goal we can’t achieve.

Explore Limitless Magazine

The post LIMITLESS Magazine appeared first on MassBio.

Watch our TandemViz demo here

To learn more or to set up a demo on your system contact John Geanacopoulos, Director of BD: john.geanacopoulos@tandemai.com

The post TandemAI launches Tandemviz, the computational suite that changes your approach to compound design appeared first on MassBio.

Zurich, Switzerland – November 16, 2023

InSphero AG, the global leader in 3D cell culture technologies and organ-on-chip systems for drug discovery, and ATCC, the world’s premier biological materials management and standards organization, will work together to introduce new paradigms in the rapidly evolving field of 3D cell-based oncology research.

Unlock access to an expansive and diverse portfolio of 3D tumor models

A primary objective of this collaboration is to give the scientific and research communities unprecedented access to assay-ready 3D tumor microtissues. This is made possible by synergistically coupling ATCC’s authenticated cells with InSphero’s innovative, industry-leading 3D cell-based assay platforms. Moreover, the partnership will provide an expansive and diverse portfolio of tumor models, ensuring researchers have access to enriched data sets that underpin better decision-making in drug discovery and development.

Advancing cancer research through uniform, reproducible, and scalable 3D tissue models from high-quality cell lines

“Through this partnership with ATCC, we are fulfilling a long-standing ambition to open new avenues for advancing cancer research at a global scale,” said Dr. Jan Lichtenberg, CEO of InSphero. “By supplying assay-ready 3D tumor microtissues based on ATCC cells, we’re not only significantly accelerating research timelines but also setting a new gold standard for uniformity and reproducibility in the research community.”

In addition to offering innovative products, InSphero will provide educational webinars and workshops with ATCC’s support to promote awareness and training around this cutting-edge technology. These efforts aim to equip the research community with the essential tools they need for the efficient generation of high-quality data.

“The combination of InSphero’s technology with ATCC’s high-quality cell lines to generate 3D models in a convenient format will greatly benefit the oncology research community,” said Dr. Ruth Cheng, ATCC Senior Vice President and General Manager, Research & Industrial Solutions. “This partnership is an important advancement in oncology drug discovery and development toward the next generation of therapies.”

https://insphero.com/insphero-to-revolutionize-oncology-research-through-advanced-3d-cell-based-assays-with-atcc/

The post InSphero to Revolutionize Oncology Research Through Advanced 3D Cell-Based Assays with ATCC appeared first on MassBio.

Click here to listen to how we help our customers commercialize their products through multiple phases such as product design & development, manufacturing, supply chain management, and worldwide fulfillment.

The post LaunchWorks featured on “Life Science Marketing Radio” appeared first on MassBio.